Business
Zentek Provides Update on Rapid Detection Technology
GUELPH, ON / ACCESSWIRE / November 9, 2021 / Zentek Ltd.  (" ZEN " or the " Company ")...
About this update from Zentek Ltd.
[{"type":"text","content":"Zentek Provides Update on Rapid Detection TechnologyGUELPH, ON / ACCESSWIRE / November 9, 2021 / Zentek Ltd. (\"ZEN\" or the \"Company\") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, is pleased to provide an update on its leading-edge rapid detection platform:ZEN has contracted NeoVentures Biotechnology Inc. - a world leader in aptamer development and applications - which has validated the McMaster results against spike proteins and is currently optimizing and simplifying the technology in preparation for regulatory submission and commercial production. NeoVentures and ZEN are also working to develop a model to further improve detection limits and sensitivityZEN has contracted axiVEND - specialists in the development and production of biosensors - to optimize the automated process of producing sensors on which customized aptamers will be depositedThrough consultation with potential partners and in tandem with McMaster, developed an improved aptamer with a higher binding affinity for the COVID-19 Delta variant.Reduced the three-buffer methodology developed by the McMaster team to a two-buffer approach to simplify the user experience which would more easily support widespread adoptionOptimized the production time of the aptamer-based sensor from 18 hours to 30 minutes with more consistent resultsFormalizing a research collaboration with McMaster to develop and produce new aptamers for high-priority, communicable pathogens on a recurring basisIn active discussions with partners for key aspects of the supply chain and detection platform, including consumables, hardware, software and data management\"In collaboration with our partners, including Dr. Li and his entire McMaster team, we have made tremendous progress advancing our aptamer-based rapid detection platform toward commercialization. A key aspect of the technology is its adaptability through the production of new aptamers to detect different pathogens leveraging the existing platform - and the process of building out this aptamer and disease-detection library is well underway with our colleagues at McMaster.We believe our combination of accuracy, speed, ease of use, scalability and affordability is unique in the market, and we will continue working diligently with our par...